Recurrent Uterine Corpus Carcinosarcoma
2 clinical trials · Condition
◉ Watch Recurrent Uterine Corpus Carcinosarcoma
| Record | Firm | Date |
|---|---|---|
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer (NCT04906382) | Floor Backes, MD | 2021-07-01 |
| VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (NCT03120624) | Mayo Clinic | 2017-09-15 |
Track Recurrent Uterine Corpus Carcinosarcoma automatically
Every clearance here is in the API, with alerts when new ones post.